Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 11, 2026

Company name:	SHIONOGI & CO., LTD.
Representative:	Isao Teshirogi, Representative Director, President and CEO
Stock Code:	4507 (Prime Market of the Tokyo Stock Exchange)
Contact:	Yoshimasa Kyokawa, Vice President, Corporate Communications Department (TEL.06-6202-2161)

(Corrections / Correction of Numerical Data) Corrections to the Consolidated Financial Results for the Second Quarter of Fiscal Year 2026 (IFRS)

SHIONOGI & CO., LTD. hereby announced the following corrections to its “Consolidated Financial Results for the Second Quarter of Fiscal Year 2026 (IFRS)” disclosed on October 29, 2026. As numerical data (XBRL) has also been corrected, the corrected numerical data is also sent.

1. Reason for corrections

   Due to errors in part of the content stated on the attachment of the above-mentioned disclosure material released, “1. Overview of Operating Results and Financial Position (3) Cash Flows for the Second Quarter of the Fiscal Year Ending March 31, 2027” and “2. Consolidated Financial Statements and Notes (4) Consolidated statement of cash flows”, we hereby issue these corrections.

   These corrections were made due to errors identified in the calculation process of “Dividends received from entities accounted for using equity method,” which has been separately presented since the second quarter of the fiscal year ending March 31, 2027. Accordingly, the related items have been corrected.

2. Details of corrections

   The corrected items are underlined.

（Before correction）

1. Overview of Operating Results and Financial Position

(3) Cash Flows for the Second Quarter of the Fiscal Year Ending March 31, 2027

Net cash provided by operating activities during the six months ended September 30, 2026 was 142,166 million yen, an increase of 50,675 million yen year on year, due to increases in profit before tax, and depreciation and amortization.

Net cash used in investing activities was 434,663 million yen, an increase of 231,675 million yen year on year, mainly due to payments for acquisition of businesses in connection with the acquisition of the edaravone business from Tanabe Pharma.

Net cash used in financing activities was 35,431 million yen, an increase of 5,071 million yen year on year, mainly due to an increase in cash dividends paid.

As a result, cash and cash equivalents on September 30, 2026 totaled 376,482 million yen, a decrease of 332,075 million yen during the six-month period ended September 30, 2026.

（After correction）

1. Overview of Operating Results and Financial Position

(3) Cash Flows for the Second Quarter of the Fiscal Year Ending March 31, 2027

Net cash provided by operating activities during the six months ended September 30, 2026 was 142,605 million yen, an increase of 51,114 million yen year on year, due to increases in profit before tax, and depreciation and amortization.

Net cash used in investing activities was 434,663 million yen, an increase of 231,675 million yen year on year, mainly due to payments for acquisition of businesses in connection with the acquisition of the edaravone business from Tanabe Pharma.

Net cash used in financing activities was 35,431 million yen, an increase of 5,071 million yen year on year, mainly due to an increase in cash dividends paid.

As a result, cash and cash equivalents on September 30, 2026 totaled 376,482 million yen, a decrease of 332,075 million yen during the six-month period ended September 30, 2026.

（Before correction）

2. Consolidated Financial Statements and Notes

(4) Consolidated statement of cash flows

Millions of yen

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from operating activities		
Profit before tax	97,590	107,257
Depreciation and amortization	10,306	41,861
Impairment losses (reversal of impairment losses)	—	5,082
Share of profit (loss) of investments accounted for using the equity method	540	(23,087)
Finance income and finance costs	(27,048)	2,699
Decrease (increase) in trade and other receivables	6,051	(12,524)
Decrease (increase) in inventories	(9,542)	14,482
Increase (decrease) in trade and other payables	(8,395)	(23,274)
Other	2,909	10,816
Subtotal	72,412	123,312
Interest and dividends received	34,483	3,466
Dividends received from entities accounted for using equity method	—	38,270
Interest paid	(148)	(3,870)
Income taxes refund (paid)	(15,255)	(19,012)
Net cash provided by (used in) operating activities	91,491	142,166
Cash flows from investing activities		
Payments into time deposits	(103,772)	(89,714)
Proceeds from withdrawal of time deposits	71,919	1,455
Purchase of property, plant and equipment	(7,282)	(10,766)
Purchase of intangible assets	(5,709)	(8,925)
Purchase of investments	(70,370)	(4,812)
Proceeds from sale and redemption of investments	31,005	70,621
Payments for acquisition of businesses	—	(390,757)
Proceeds (payments) for acquisition of subsidiaries	4,414	—
Payment for acquisition of shares of equity-method affiliates	(76,656)	—
Payments for loans receivable	(45,000)	—
Other	(1,535)	(1,764)
Net cash provided by (used in) investing activities	(202,988)	(434,663)

Millions of yen

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from financing activities		
Repayments of lease liabilities	(1,915)	(2,584)
Purchase of treasury shares	(3)	(1)
Dividends paid	(28,104)	(32,355)
Dividends paid to non-controlling interests	(337)	(490)
Net cash provided by (used in) financing activities	(30,360)	(35,431)
Effect of exchange rate changes on cash and cash equivalents	926	(4,147)
Net increase (decrease) in cash and cash equivalents	(140,930)	(332,075)
Cash and cash equivalents at beginning of period	374,795	711,397
Net increase (decrease) in cash and cash equivalents included in assets held for sale	—	(2,839)
Cash and cash equivalents at end of period	233,864	376,482

（After correction）

2. Consolidated Financial Statements and Notes

(4) Consolidated statement of cash flows

Millions of yen

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from operating activities		
Profit before tax	97,590	107,257
Depreciation and amortization	10,306	41,861
Impairment losses (reversal of impairment losses)	—	5,082
Share of profit (loss) of investments accounted for using the equity method	540	(23,087)
Finance income and finance costs	(27,048)	2,699
Decrease (increase) in trade and other receivables	6,051	(12,524)
Decrease (increase) in inventories	(9,542)	14,482
Increase (decrease) in trade and other payables	(8,395)	(23,274)
Other	2,909	10,816
Subtotal	72,412	123,312
Interest and dividends received	34,483	10,983
Dividends received from entities accounted for using equity method	—	31,192
Interest paid	(148)	(3,870)
Income taxes refund (paid)	(15,255)	(19,012)
Net cash provided by (used in) operating activities	91,491	142,605
Cash flows from investing activities		
Payments into time deposits	(103,772)	(89,714)
Proceeds from withdrawal of time deposits	71,919	1,455
Purchase of property, plant and equipment	(7,282)	(10,766)
Purchase of intangible assets	(5,709)	(8,925)
Purchase of investments	(70,370)	(4,812)
Proceeds from sale and redemption of investments	31,005	70,621
Payments for acquisition of businesses	—	(390,757)
Proceeds (payments) for acquisition of subsidiaries	4,414	—
Payment for acquisition of shares of equity-method affiliates	(76,656)	—
Payments for loans receivable	(45,000)	—
Other	(1,535)	(1,764)
Net cash provided by (used in) investing activities	(202,988)	(434,663)

Millions of yen

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from financing activities		
Repayments of lease liabilities	(1,915)	(2,584)
Purchase of treasury shares	(3)	(1)
Dividends paid	(28,104)	(32,355)
Dividends paid to non-controlling interests	(337)	(490)
Net cash provided by (used in) financing activities	(30,360)	(35,431)
Effect of exchange rate changes on cash and cash equivalents	926	(4,586)
Net increase (decrease) in cash and cash equivalents	(140,930)	(332,075)
Cash and cash equivalents at beginning of period	374,795	711,397
Net increase (decrease) in cash and cash equivalents included in assets held for sale	—	(2,839)
Cash and cash equivalents at end of period	233,864	376,482